Referring Clinicians
Trials Recruiting at ACTC
| Tumour Stream | Trial Name | Study Description | Key Investigational Agent | Key Inclusion Criteria | Recruitment Status |
|---|---|---|---|---|---|
| Advanced Solid Organ Tumours | GILEAD (GS-US-494-5484) | A Phase 1b/2 Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of GS-4224 in Subjects with Advanced Solid Tumors | GS-4224 (small molecule oral PDL1 Inhibitor) Daily dosing, 3 week cycles | Advanced Solid Organ Malignancy with no further treatment options. - Biopsy substudy (1000mg daily): CPS >10% on pre-screening of archival tissue - Dose Escalation Cohort (1000mg BD): Checkpoint inhibitor naïve metastatic melanoma, NSCLC, clear cell RCC, urothelial, gastric, HNSCC, hepatocellular carcinoma, Merkel cell, esophageal SCC, cutaneous SCC and MSI-H cancers (each tumour type has a pre-specified TPS levels for eligibility) | Both cohorts recruiting |
| Oesophageal SCC | NP40435 | Phase 1b study to evaluate safety, pharmacokinetic and preliminary anti-tumour activity of R07121661, PD-l/TIM3 Bispecific Antibody in patients with advanced and/or metastatic solid tumours | PD1/TIM3 bi-specific antibody 2 weekly infusions | - Oesophageal: squamous or adeno-squamous, not more than 1 line of treatment for metastatic disease or recurrence within 24 weeks after chemo-RT/ surgical resection. | Recruiting |
| Cervical | AK104-201-AU | A Phase 2, global, multicenter, open-label, single-arm study designed to evaluate the efficacy, safety, tolerability, pharmacokinetic (PK), and immunogenicity of AK104 monotherapy in adult subjects with previously treated recurrent or metastatic cervical carcinoma. | AK104 (bispecific antibody targeting CTLA4/ PD-1) Fortnightly infusion | •Previously treated recurrent or metastatic squamous carcinoma or adeno-squamous carcinoma of the cervix: o Disease progression during or following platinum doublet o No more than 2 prior systemic therapies in recurrent/ metastatic setting o Not eligible for surgery or radiation as treatment for recurrent disease o Available archival tissue for PD-L1 assessment. | Recruiting |
| NSCLC, RCC | CA20976U | A Phase 1/2 Pharmacokinetic Multi-tumor Study of Subcutaneous Formulation of Ipilimumab and in Combination with Subcutaneous Nivolumab | S/C Ipilimumab (6 weekly) + S/C Nivolumab (2 weekly) administered with rHuPH20 (recombinant human hyaluronidase) | Part 2 o Metastatic NSCLC: Opening soon. Treatment naïve stage IV . Prior adjuvant chemo +/- RT allowed as long as > 6 months from time of completion. o RCC: No prior treatment lines for stage IV or recurrent disease, IMDC intermediate and poor risk only. | Opening soon |
| Advanced solid tumours with established IO indication | BGB-A317-A445-101 | Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of the Anti-OX40 Agonist Monoclonal Antibody BGB-A445 in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | BGB-A445 (OX40 agonist) and Tislelizumab (PD-1 inhibitor) Three weekly infusions | • Phase 1a: Dose Escalation: Includes BGB-A445 monotherapy cohorts and combination cohorts with tislelizumab. Recruitment opens intermittently. • Dose Expansion: Closed until phase 1a completed. Details to follow. | Phase 1a recruiting |
| Metastatic Melanoma | MK1308-001 (Checkmate 76U) | A Phase 1/2 Pharmacokinetic Multi-tumor Study of Subcutaneous Formulation of Ipilimumab Monotherapy and in Combination with Subcutaneous Nivolumab | MK1308A (Co-formulation of MK1308 (CTLA4 inh) + pembrolizumab | -Cohort J o Unresectable stage III or metastatic melanoma o Confirmed progression on scan after PD1/PDL1 monotherapy or in combination with other therapies excluding prior CTLA4 inhibitor exposure. o BRAF v600 mutation positive disease accepted provided that participants have/ are still receiving targeted therapy OR remains asymptomatic with no evidence of rapid progression and LDH Opening soon |
|
How to Refer
Please email all referrals to CentralReferrals@adhb.govt.nz (include Att: ACTC in email subject)
Email us for any other inquiries: infoACTC@adhb.govt.nz
Auckland Cancer Trials Centre
Auckland City Hospital,
2, Park Road, Grafton,
1023, Auckland, New Zealand
Patient Referrals
Please email all referrals to: CentralReferrals@adhb.govt.nz (include Att: ACTC in email subject)